Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology Inc (NQ: VIR )

7.435 +0.315 (+4.42%)
Streaming Delayed Price Updated: 1:54 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology Inc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
7 Healthcare Stocks That Will Be Big Winners in 2023
Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider. 
Via InvestorPlace
5 Value Stocks In The Healthcare Sector
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
Via Benzinga
Analyst Expectations for Vir Biotechnology's Future
Via Benzinga
2 Fast-Growing Healthcare Stocks to Buy and Hold
The innovative companies have made great gains in a short period of time. 
Via The Motley Fool
Data From Multiple Ongoing Trials Of Vir Biotech's HBV Therapies Show Promising Action
Via Benzinga
Why Vir Biotechnology Jumped Nearly 19% Today
A COVID-19 partnership with a major drugmaker is producing more fruit than expected. 
Via The Motley Fool
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
From Vir Biotechnology, Inc.
Via GlobeNewswire
2 Stocks That Could Turn $100 Into $1,000 by 2028
These growth stocks have substantial tailwinds. 
Via The Motley Fool
Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
– Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 – 
From Vir Biotechnology, Inc.
Via GlobeNewswire
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding... 
Via Benzinga
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather... 
Via Benzinga
After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade
Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust. 
Via Benzinga
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
From Vir Biotechnology, Inc.
Via GlobeNewswire
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
FDA Moves Step Closer For Opioid Overdose Medication Access, Says Certain Naloxone Products Can Potentially Be Used In OTC Setting
Via Benzinga
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection
From Vir Biotechnology, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
Gainers 
Via Benzinga
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
What 5 Analyst Ratings Have To Say About Vir Biotechnology
Over the past 3 months, 5 analysts have published their opinion on Vir Biotechnology (NASDAQ:VIR) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth
Sales of Vir Biotechnology and GSK's Covid antibody almost tripled sales estimates. 
Via Investor's Business Daily
Block, MasTec, Universal Display And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Vir Biotechnology, Inc.
Via GlobeNewswire
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion. 
Via Benzinga
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
From Vir Biotechnology, Inc.
Via GlobeNewswire
Boston University's COVID-19 Created In Lab Research Comes Under Scrutiny
Boston University created an artificial form of COVID-19 in a laboratory. Now, U.S. health officials have launched an inquiry into a controversial study. The Boston University research was designed to... 
Via Benzinga
This Addiction Drug Shows Some Potential Against Long COVID Symptoms
Researchers are working on cures for long COVID. With some success, naltrexone has been used to treat pain, fatigue, and brain fog months after a coronavirus infection. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.